Evidence map›Paper›PMID 40788065›Full record

SynthesisAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025

Tumor Extracellular Vesicles Aggravate Mitochondrial Damage in Myocardial Ischemia/Reperfusion Injury.

Zhongting Mei, Qian Liu, Guoxin Liu, Manjie Zhang, Jiaxin Fang, Xuting He, Xueqi He, Zhengwei Qin, Ronghua Liu, Chuang Liu and 5 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Zhongting MeiState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Qian LiuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Guoxin LiuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Manjie ZhangDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Jiaxin FangDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Xuting HeDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Xueqi HeDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Zhengwei QinDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Ronghua LiuDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Chuang LiuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Hongyu JiDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Yuechao DongState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Ye YuanDepartment of Pharmacy at the Second Affliated Hospital, State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Harbin medical university, Harbin, 150081, China.
Baofeng YangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.
Weijie DuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology (State Key Laboratoray-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, 150081, China.ORCID https://orcid.org/0000-0003-1197-1462

Funding

Chunyan programme of Heilongjiang Province CYQN2403Distinguished Young Scholars of Natural Science Foundation of Heilongjiang Province JQ2024H002National Natural Science Foundation of China 82330011National Natural Science Foundation of China 82473919Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0537900Noncommunicable Chronic Diseases-National Science and Technology Major Project 2024ZD0537909
6 · The paper itself

Abstract

Cancer patients have a higher risk of all types of cardiovascular diseases (CVDs). Cardiologists are encountering a growing number of cancer patients with CVDs, and an increasing number of cancer patients undergoing percutaneous coronary intervention (PCI). The mechanistic link between cancer and CVDs remains elusive. Here, the meta-analysis shows the increased incidence ratio of all-cause mortality and cardiovascular (CV) mortality in patients undergoing PCI with cancer compared with non-cancer. We experimentally demonstrated that cancer aggravated mitochondrial dysfunction and myocardial ischemia/reperfusion (I/R) injury in two models of lung cancer in mice. Plasma extracellular vesicles (EVs) derived from cancer mice exacerbated cardiac I/R injury in vivo and in vitro, while inhibition of tumor EVs secretion by lipid-coated polyacrylic acid/calcium phosphate nanoparticles delivered a neutral sphingomyelinase inhibitor (GW4869) showed the opposite results. Lung-specific miR-485-3p sponges mediated by Adeno-associated virus 6 suppress cardiac damage and mitochondrial dysfunction in CC10-KRAS

Indexed as

Extracellular VesiclesLung NeoplasmsMitochondriaMyocardial Reperfusion InjuryAnimalsDisease Models, AnimalHumansMaleMiceMicroRNAsMicroRNAscancerextracellular vesiclesmiR‐485‐3pmitochondrial dysfunctionmyocardial ischaemia/reperfusionpercutaneous coronary interventionPPARGC1A/PGC‐1α

Identifiers

PMID40788065
PMCPMC12462958

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.